Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

66.91 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
49 50 Next >
AstraZeneca Stock Tumbles After Q4 Performance - Here's Why
AstraZeneca Q4 2023: $12.02 billion sales, 7% Y/Y growth, fueled by global demand for cancer drugs. Excluding COVID-19 meds, revenue rises 16%. CEO Soriot projects low double-digit growth in 2024. 
Via Benzinga
Exposures COVID-19
AstraZeneca Downgraded On "Underwhelming" Q4 Earnings
AZN stock took a header early Thursday after a mixed Q4 report and a downgrade to sell on "thoroughly underwhelming" results. 
Via Investor's Business Daily
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
Earnings Outlook For AstraZeneca
Via Benzinga
NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?
The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs. 
Via InvestorPlace
History Says the Nasdaq Will Keep Soaring in 2024. Here's the Surprising Megacap Stock Wall Street Thinks Will Be the Biggest Winner.
Hint: It's not Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, or Tesla. 
Via The Motley Fool
Check Out What Whales Are Doing With AZN
Via Benzinga
Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry
Via Benzinga
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market. 
Via Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
A reasonably modest amount of money can go a long way when it's put to work in industry-leading businesses. 
Via The Motley Fool
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
3 Magnificent Stocks to Buy and Hold Forever
Many investors will want to consider owning these stocks for a long time. 
Via The Motley Fool
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
Exposures Product Safety
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech... 
Via Talk Markets
AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study
Explore results from AstraZeneca's EMERALD-1 Phase 3 trial on Imfinzi for unresectable hepatocellular carcinoma. Statistically significant improvement in progression-free survival with Imfinzi plus... 
Via Benzinga
Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold
Be sure to sell these meme stocks as they represent fundamentally weak businesses that will continue to erode in value. 
Via InvestorPlace
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed... 
Via Benzinga
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst. 
Via Investor's Business Daily
Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense
Join the fight against Nipah virus! Oxford Vaccine Group launches groundbreaking ChAdOx1 NipahB vaccine trial, targeting the deadly virus. 51 participants aged 18-55. Funded by CEPI. Help combat Nipah... 
Via Benzinga
Exposures COVID-19
4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-fueled Nasdaq Composite is 9% below its record high, meaning amazing deals are still hiding in plain sight. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Exposures Product Safety
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
Key Takeaways: AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price 
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024
These are the undervalued and fundamentally strong dividend-paying stocks to buy for high total returns in the next 24 to 36 months. 
Via InvestorPlace
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. 
Via InvestorPlace
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD 
Via Benzinga
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... 
Via Talk Markets
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. 
Via Benzinga
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
The major indexes boast big annual gains with the Dow at record highs. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.